Viridian Therapeutics, Inc. Tech Stack

Clinical-stage biotech developing antibody therapeutics for autoimmune diseases

Biotechnology Research Waltham, Massachusetts 51–200 employees Founded 2007 Public Company

Viridian is a public biopharmaceutical company advancing multiple clinical candidates—primarily VRDN-001 (IV) and VRDN-003 (subcutaneous) for thyroid eye disease, plus a portfolio of FcRn inhibitors for broader autoimmune indications. The tech stack reflects a transitional biotech: clinical-grade analytics (SAS, R, CDISC, JMP, GraphPad Prism) paired with commercial-stage infrastructure (Veeva for CRM and safety, Tableau/Power BI for reporting, Kubernetes for deployment). Hiring is sales-heavy (102 roles) and decelerating, aligned with active projects centered on first commercial launch and buildout of a field-facing commercial organization—typical of a company moving from development into commercialization.

Tech Stack 23 technologies

Core StackSAS Tableau Power BI Kubernetes Terraform CloudFormation R CDISC UKG IQVIA Microsoft Office Word PowerPoint Excel Outlook SharePoint JMP GraphPad Prism Minitab FlowJo Veeva PromoMats Veeva CRM Veeva Safety

What Viridian Therapeutics, Inc. Is Building

◆Challenges

Transition to fully operational commercial organization
Minimizing access barriers
Overcoming access challenges
Lifecycle management of pipeline assets
First commercial launch
Preparing for product launches
Ensuring consistent compliance
Ensuring consistent support experience
Cleaning uncleaned data
Operational governance

▲Active Projects

First commercial launch
Transition to fully operational commercial organization
Territory execution & strategic alignment
Training of viridiancares
Field-facing reporting
Pipeline screening assays
Product launch plans
Viridian ted program
Sop development
Ppk/pkpd/er dataset preparation and exploratory data visualization

Hiring Activity

Decelerating150 roles · 20 in 30d

Department

Sales

102

Healthcare

Support

Ops

Research

Marketing

Compliance

Data

Seniority

Senior

109

Director

Mid

Manager

Junior

Lead

Principal

Notable leadership hires: Medical Director

Company intelligence

Find more companies like Viridian Therapeutics, Inc. by tech stack, pain points and active projects

Get started free

About Viridian Therapeutics, Inc.

Viridian Therapeutics is a public biopharmaceutical company headquartered in Waltham, Massachusetts, focused on antibody discovery and protein engineering for serious and rare autoimmune diseases. The company is advancing two global Phase 3 trials (THRIVE and THRIVE-2) evaluating VRDN-001 as an intravenous therapy for thyroid eye disease, with VRDN-003 in development as a subcutaneous follow-on candidate. Beyond TED, Viridian is developing a pipeline of neonatal Fc receptor inhibitors (VRDN-006, VRDN-008) with potential across multiple autoimmune indications. The organization operates across 51–200 employees in the United States, with infrastructure spanning clinical operations, regulatory/safety compliance (Veeva), and early commercial buildout.

HeadquartersWaltham, Massachusetts

Company Size51–200 employees

Founded2007

Hiring MarketsUnited States

Frequently Asked Questions

What is Viridian Therapeutics working on?

Two Phase 3 programs for thyroid eye disease (VRDN-001 as IV therapy, VRDN-003 as subcutaneous), plus a portfolio of FcRn inhibitors (VRDN-006, VRDN-008) targeting multiple autoimmune diseases. Active projects include first commercial launch, commercial organization buildout, and pipeline screening assays.

What tech stack does Viridian Therapeutics use?

Clinical analytics (SAS, R, CDISC, JMP, GraphPad Prism), commercial infrastructure (Veeva CRM, Veeva PromoMats, Veeva Safety), BI tools (Tableau, Power BI), cloud/infrastructure (Kubernetes, Terraform, CloudFormation), and standard Microsoft Office suite.